Bolli GB, Porcellati F, Lucidi P, Fanelli CG, et al. Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin)
During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in
People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136. Diabetes Care 2021;44:e59-e60.
PMID: 33608328